ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 283

Extracellular Histidyl-tRNA Synthetase in Myositis

Catia Fernandes-Cerqueira1, Azita Sohrabian2, Inka Albrecht1, Antonella Notarnicola1, Elena Ossipova1, Johan Lengqvist1, Kim Kultima3, Maryam Fathi4, Ger JM Pruijn5, Johan Grunewald4, Johan Rönnelid2, Ingrid E. Lundberg1 and Per-Johan Jakobsson1, 1Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Department of Immunology Genetics and Pathology,Uppsala University, Uppsala, Sweden, 3Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Uppsala University, Uppsala, Sweden, 4Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: lung and myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Histidyl-transfer RNA synthetase (HisRS, Jo-1) is a major autoantigen in myositis with lung involvement1-4. Simultaneous presence of anti-Jo-1 and anti-Ro52 antibodies has been demonstrated in patients with myositis5-7. We investigated the presence of HisRS in the extracellular compartments plasma, sera and bronchoalveolar lavage fluid (BALF). In addition, the occurrence of anti-Jo-1 antibody isotypes as well as anti-nuclear antibodies (ANA) was evaluated in BALF and sera from patients with myositis.

Methods: HisRS was measured in sera, plasma and BALF from patients with myositis (in both anti-Jo-1 positive and anti-Jo-1 negative patients), sarcoidosis, rheumatoid arthritis (RA) and healthy controls (HC) by dot-blot, western-blot, immunoprecipitation and mass spectrometry. The presence in BALF and sera of anti-Jo-1 isotypes and ANA was analysed by ELISA and addressable laser bead immunoassay.

Results: HisRS was detected in sera, plasma and BALF of patients with myositis, sarcoidosis and RA, and in HC. Systemic HisRS levels were significantly elevated in anti-Jo-1 positive myositis (14 out of 20 sera) compared to anti-Jo-1 negative myositis (10/18), sarcoidosis (0/8) and RA (3/15) patients, and HC (5/23). In BALF, significant levels of HisRS were detected in 6/8 HC and 5/8 sarcoidosis, compared to 4/8 myositis (2 anti-Jo-1 positive and 2 anti-Jo-1 negative). Our results suggest the presence of a factor in BALF with high binding capacity for HisRS and HisRS complexed with anti-HisRS-N-terminal antibody. C1q-immune complexes (IC) binding HisRS were not the binding factor. However, anti-Jo-1 antibodies as well as anti-Ro52 IgG were identified in myositis BALF (5/8 patients were positive for anti-Jo1 IgG, 3/8 for anti-Jo1 IgA, 3/8 for anti-Jo1 IgM and 4/8 for anti-Ro52 IgG). Furthermore, a positive correlation between the presence of anti-Jo-1 IgG and anti-Ro52 IgG in myositis BALF was identified (r2=0.881; p=0.007).

Conclusion: HisRS was detected both in blood and BALF. The identification of extracellular HisRS, anti-Jo-1 isotypes and anti-Ro52 IgG in myositis BALF may provide additional clues for the development of autoimmunity in the lungs. 1Bernstein RM et al Br Med J (Clin Res Ed). 1984 Jul 21;289(6438):151-2; 2Marguerie C et al Q J Med. 1990 Oct;77(282):1019-38; 3Hervier B et al Eur Respir J. 2013 Nov;42(5):1271-82; 4Hamaguchi Y et al PLoS One. 2013;8(4):e60442; 5La Corte R et al Autoimmunity 2006 May;39(3):249-53; 6Brouwer R et al Ann Rheum Dis. 2001 Feb;60(2):116-23; 7Rutjes SA et al Clin Exp Immunol. 1997 Jul;109(1):32-40.


Disclosure: C. Fernandes-Cerqueira, None; A. Sohrabian, None; I. Albrecht, Sanofi Genzyme, 3; A. Notarnicola, None; E. Ossipova, None; J. Lengqvist, None; K. Kultima, None; M. Fathi, None; G. J. Pruijn, ModiQuest, 4; J. Grunewald, None; J. Rönnelid, None; I. E. Lundberg, Bristol-Myers Squibb, 2,Bristol-Myers Squibb, 5,Idera, 5,AstraZeneca, 2,ATyr, 9; P. J. Jakobsson, None.

To cite this abstract in AMA style:

Fernandes-Cerqueira C, Sohrabian A, Albrecht I, Notarnicola A, Ossipova E, Lengqvist J, Kultima K, Fathi M, Pruijn GJ, Grunewald J, Rönnelid J, Lundberg IE, Jakobsson PJ. Extracellular Histidyl-tRNA Synthetase in Myositis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/extracellular-histidyl-trna-synthetase-in-myositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extracellular-histidyl-trna-synthetase-in-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology